News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

As Deadline Nears, Suitor Genzyme Corporation (GENZ) May Have to Revise Bid For Sanofi-Aventis K.K.


12/10/2010 8:15:47 AM

Boston Globe -- Sanofi-Aventis SA’s hostile tender offer for Genzyme Corp. expires at midnight tonight. But so far, the French drug maker has given no indication of how many stockholders have agreed to turn over their shares. Because shares of the Cambridge biotechnology company are still trading above the $69 that Sanofi has offered in its $18.5 billion bid, it is doubtful that many Genzyme investors will opt to cash out.

Read at Boston Globe
Read at Reuters
Read at Wall Street Journal


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES